Formycon AG (LON:0W4N)
25.20
-0.30 (-1.18%)
At close: Dec 5, 2025
Formycon AG Revenue
Formycon AG had revenue of 9.00M EUR in the half year ending June 30, 2025, a decrease of -79.45%. This brings the company's revenue in the last twelve months to 48.07M, down -17.19% year-over-year. In the year 2024, Formycon AG had annual revenue of 69.67M, down -10.32%.
Revenue (ttm)
48.07M EUR
Revenue Growth
-17.19%
P/S Ratio
9.17
Revenue / Employee
192.30K EUR
Employees
250
Market Cap
384.82M GBP
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 69.67M | -8.02M | -10.32% |
| Dec 31, 2023 | 77.70M | 35.20M | 82.83% |
| Dec 31, 2022 | 42.50M | 5.88M | 16.07% |
| Dec 31, 2021 | 36.61M | 2.32M | 6.76% |
| Dec 31, 2020 | 34.30M | 1.14M | 3.43% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.24B |
| GSK plc | 32.17B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Hikma Pharmaceuticals | 2.35B |
| Convatec Group | 1.72B |
| Genus | 672.80M |
| HUTCHMED (China) | 439.54M |
Formycon AG News
- 16 days ago - Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy • news - Onvista
- 21 days ago - Formycon AG 2025 Q3 - Results - Earnings Call Presentation - Seeking Alpha
- 22 days ago - Positioning Barbados as the Caribbean's Life Sciences Hub - Benzinga
- 23 days ago - Formycon AG (XTER:FYB) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Revenue Challenges - GuruFocus
- 23 days ago - Q3 2025 Formycon AG Earnings Call Transcript - GuruFocus
- 23 days ago - Formycon AG (FYBGF) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Formycon, Teva Pharma Launch FYB201/Ranivisio Biosimilar In Pre-filled Syringe In Europe - Nasdaq
- 2 months ago - Formycon Reaches Settlement With Regeneron Over U.S. Eylea Biosimilar Patent Disputes - Nasdaq